51.48 USD
+2.2 (+4.46%)
51.25 USD
-0.23 (-0.45%)
Taking everything into account, SUPN scores 5 out of 10 in our fundamental rating. SUPN was compared to 192 industry peers in the Pharmaceuticals industry. SUPN has an average financial health and profitability rating. SUPN has a decent growth rate and is not valued too expensively.
1. Profitability
1.1 Basic Checks
SUPN had positive earnings in the past year.
SUPN had a positive operating cash flow in the past year.
SUPN had positive earnings in each of the past 5 years.
Each year in the past 5 years SUPN had a positive operating cash flow.
1.2 Ratios
SUPN's Return On Assets of -1.35% is fine compared to the rest of the industry. SUPN outperforms 75.00% of its industry peers.
The Return On Equity of SUPN (-1.82%) is better than 77.08% of its industry peers.
SUPN has a better Return On Invested Capital (2.34%) than 79.69% of its industry peers.
SUPN had an Average Return On Invested Capital over the past 3 years of 2.70%. This is significantly below the industry average of 12.85%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROIC | 2.34% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
1.3 Margins
SUPN's Profit Margin has declined in the last couple of years.
With a decent Operating Margin value of 6.08%, SUPN is doing good in the industry, outperforming 79.69% of the companies in the same industry.
SUPN's Operating Margin has declined in the last couple of years.
Looking at the Gross Margin, with a value of 89.91%, SUPN belongs to the top of the industry, outperforming 91.67% of the companies in the same industry.
SUPN's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% |
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so SUPN is destroying value.
Compared to 1 year ago, SUPN has more shares outstanding
Compared to 5 years ago, SUPN has more shares outstanding
SUPN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
SUPN has an Altman-Z score of 6.10. This indicates that SUPN is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of SUPN (6.10) is better than 76.56% of its industry peers.
There is no outstanding debt for SUPN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 6.1 |
ROIC/WACC0.25
WACC9.38%
2.3 Liquidity
A Current Ratio of 1.80 indicates that SUPN should not have too much problems paying its short term obligations.
The Current ratio of SUPN (1.80) is worse than 65.10% of its industry peers.
SUPN has a Quick Ratio of 1.56. This is a normal value and indicates that SUPN is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of SUPN (1.56) is worse than 60.94% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 |
3. Growth
3.1 Past
SUPN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 0.32%.
The Earnings Per Share has been growing slightly by 6.93% on average over the past years.
The Revenue has been growing slightly by 4.54% in the past year.
Measured over the past years, SUPN shows a quite strong growth in Revenue. The Revenue has been growing by 11.00% on average per year.
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
3.2 Future
The Earnings Per Share is expected to grow by 19.52% on average over the next years. This is quite good.
The Revenue is expected to grow by 14.90% on average over the next years. This is quite good.
EPS Next Y-3.99%
EPS Next 2Y21.18%
EPS Next 3Y17.74%
EPS Next 5Y19.52%
Revenue Next Year9.32%
Revenue Next 2Y16.13%
Revenue Next 3Y15.75%
Revenue Next 5Y14.9%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 16.61, the valuation of SUPN can be described as correct.
SUPN's Price/Earnings ratio is rather cheap when compared to the industry. SUPN is cheaper than 84.90% of the companies in the same industry.
SUPN is valuated rather cheaply when we compare the Price/Earnings ratio to 26.39, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 11.88 indicates a reasonable valuation of SUPN.
SUPN's Price/Forward Earnings ratio is rather cheap when compared to the industry. SUPN is cheaper than 85.42% of the companies in the same industry.
SUPN is valuated cheaply when we compare the Price/Forward Earnings ratio to 23.84, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.61 | ||
| Fwd PE | 11.88 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of SUPN indicates a somewhat cheap valuation: SUPN is cheaper than 79.69% of the companies listed in the same industry.
79.17% of the companies in the same industry are more expensive than SUPN, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 41.72 | ||
| EV/EBITDA | 20.03 |
4.3 Compensation for Growth
SUPN's earnings are expected to grow with 17.74% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)2.4
EPS Next 2Y21.18%
EPS Next 3Y17.74%
5. Dividend
5.1 Amount
No dividends for SUPN!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
51.48
+2.2 (+4.46%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners104.09%
Inst Owner Change-3.26%
Ins Owners4.25%
Ins Owner Change2.8%
Market Cap2.95B
Revenue(TTM)681.54M
Net Income(TTM)-19.12M
Analysts83.33
Price Target62.56 (21.52%)
Short Float %9.1%
Short Ratio5.69
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)77.78%
Min EPS beat(2)67.83%
Max EPS beat(2)87.73%
EPS beat(4)4
Avg EPS beat(4)62.07%
Min EPS beat(4)15.55%
Max EPS beat(4)87.73%
EPS beat(8)7
Avg EPS beat(8)65.74%
EPS beat(12)9
Avg EPS beat(12)51.6%
EPS beat(16)10
Avg EPS beat(16)29.18%
Revenue beat(2)2
Avg Revenue beat(2)5.28%
Min Revenue beat(2)5.28%
Max Revenue beat(2)5.29%
Revenue beat(4)3
Avg Revenue beat(4)4.96%
Min Revenue beat(4)-0.71%
Max Revenue beat(4)9.98%
Revenue beat(8)6
Avg Revenue beat(8)5.09%
Revenue beat(12)8
Avg Revenue beat(12)3.15%
Revenue beat(16)11
Avg Revenue beat(16)2.6%
PT rev (1m)5.38%
PT rev (3m)40.03%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-56.74%
EPS NY rev (1m)4.91%
EPS NY rev (3m)24.89%
Revenue NQ rev (1m)-1.15%
Revenue NQ rev (3m)-1.53%
Revenue NY rev (1m)0.03%
Revenue NY rev (3m)1.92%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.61 | ||
| Fwd PE | 11.88 | ||
| P/S | 4.33 | ||
| P/FCF | 41.72 | ||
| P/OCF | 41.07 | ||
| P/B | 2.81 | ||
| P/tB | 9.61 | ||
| EV/EBITDA | 20.03 |
EPS(TTM)3.1
EY6.02%
EPS(NY)4.33
Fwd EY8.41%
FCF(TTM)1.23
FCFY2.4%
OCF(TTM)1.25
OCFY2.43%
SpS11.89
BVpS18.31
TBVpS5.36
PEG (NY)N/A
PEG (5Y)2.4
Graham Number35.73
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -1.35% | ||
| ROE | -1.82% | ||
| ROCE | 3.81% | ||
| ROIC | 2.34% | ||
| ROICexc | 3.16% | ||
| ROICexgc | 38.99% | ||
| OM | 6.08% | ||
| PM (TTM) | N/A | ||
| GM | 89.91% | ||
| FCFM | 10.38% |
ROA(3y)3.02%
ROA(5y)4.13%
ROE(3y)4.71%
ROE(5y)7.54%
ROIC(3y)2.7%
ROIC(5y)4.37%
ROICexc(3y)4.39%
ROICexc(5y)6.6%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)4.82%
ROCE(5y)7.36%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y11.61%
ROICexc growth 5Y-8.56%
OM growth 3Y-9.85%
OM growth 5Y-18.4%
PM growth 3Y6.61%
PM growth 5Y-17.27%
GM growth 3Y0.96%
GM growth 5Y-1.32%
F-Score4
Asset Turnover0.48
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 1.32% | ||
| Cap/Sales | 0.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 56.66% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.8 | ||
| Quick Ratio | 1.56 | ||
| Altman-Z | 6.1 |
F-Score4
WACC9.38%
ROIC/WACC0.25
Cap/Depr(3y)0.67%
Cap/Depr(5y)5.39%
Cap/Sales(3y)0.09%
Cap/Sales(5y)0.25%
Profit Quality(3y)2940.94%
Profit Quality(5y)1832.68%
High Growth Momentum
Growth
EPS 1Y (TTM)0.32%
EPS 3Y44.39%
EPS 5Y6.93%
EPS Q2Q%-13.68%
EPS Next Y-3.99%
EPS Next 2Y21.18%
EPS Next 3Y17.74%
EPS Next 5Y19.52%
Revenue 1Y (TTM)4.54%
Revenue growth 3Y4.51%
Revenue growth 5Y11%
Sales Q2Q%9.34%
Revenue Next Year9.32%
Revenue Next 2Y16.13%
Revenue Next 3Y15.75%
Revenue Next 5Y14.9%
EBIT growth 1Y-47.81%
EBIT growth 3Y-5.79%
EBIT growth 5Y-9.43%
EBIT Next Year10.08%
EBIT Next 3Y40.06%
EBIT Next 5Y32.85%
FCF growth 1Y-23.92%
FCF growth 3Y11.03%
FCF growth 5Y4.05%
OCF growth 1Y-23.21%
OCF growth 3Y10.6%
OCF growth 5Y3.74%
SUPERNUS PHARMACEUTICALS INC / SUPN FAQ
Can you provide the ChartMill fundamental rating for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a fundamental rating of 5 / 10 to SUPN.
Can you provide the valuation status for SUPERNUS PHARMACEUTICALS INC?
ChartMill assigns a valuation rating of 5 / 10 to SUPERNUS PHARMACEUTICALS INC (SUPN). This can be considered as Fairly Valued.
What is the profitability of SUPN stock?
SUPERNUS PHARMACEUTICALS INC (SUPN) has a profitability rating of 5 / 10.
What is the valuation of SUPERNUS PHARMACEUTICALS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for SUPERNUS PHARMACEUTICALS INC (SUPN) is 16.61 and the Price/Book (PB) ratio is 2.81.
How financially healthy is SUPERNUS PHARMACEUTICALS INC?
The financial health rating of SUPERNUS PHARMACEUTICALS INC (SUPN) is 6 / 10.